Shanghai, China, 30 December 2022 - Recently, six products independently developed by Endovastec™ (SSE: 688016) have been approved by the Ministry of Health of Belarus for registration. This marks the first time that Endovastec™ has obtained product approvals in Belarus, laying a solid foundation for the company to enter the market.
Currently, the Endovastec™ products approved for marketing in Belarus include the Castor® Branched Aortic Stent-Graft and Delivery System, Hercules® Low Profile Straight Tube-Type Stent-Graft and Delivery System, Minos® Abdominal Aortic Stent-Graft and Delivery System, Hercules® Bifurcated Stent-Graft and Delivery System, CRONUS® Intraoperative Stent System (CRONUS®), and Hercules® Balloon Dilatation Catheter. These are the six core Endovastec™ products in the field of aortic therapy, encompassing thoracic endovascular aortic repair, abdominal aortic endoluminal therapy, and surgeries.
The Castor® Branched Aortic Stent-Graft and Delivery System is for endoluminal treatment of lesions involving the aortic arch and is the first of its kind in the world approved for marketing.. It has been marketed in 7 countries with over 13,000 implantations worldwide in the last 5 years. The Minos® Abdominal Aortic Stent-Graft and Delivery System is a new-generation product independently developed by Endovastec™ for abdominal aortic therapy. It is also the first domestic product that reduces the sheath of the delivery device to 14F. Launched in China in 2019, it has entered 14 markets with more than 4,000 implantations worldwide and has been widely recognized and praised by experts at home and abroad for its excellent clinical performance. CRONUS® is an intraoperative stent system for thoracic aortic coarctation surgery, which enables the combination of two open-heart surgeries into one single operation. It can significantly reduce the trauma and difficulty of surgery, lessen patients’ pain, and improve the surgical cure rate. The CRONUS® surgical technology has been promoted in China and abroad, and has been clinically applied to more than 60,000 cases.
Among domestic brands of aortic products, Endovastec™ has enjoyed the largest market share in China for years. The approval of the six aortic products in Belarus is also a strategic globalization move for Endovastec™ to enter emerging markets abroad while continuing its penetration in the domestic mature market. This initiative lays the foundation for the company’s future expansion into the Eastern European market as well as accelerated coverage of the global market. In the future, Endovastec™ will continue its effort to introduce more high-quality and high-end innovative medical devices to global markets, bringing better medical solutions for blood circulation diseases to patients and physicians worldwide.
Founded in 2012, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™; SSE: 688016), a subsidiary of MicroPort Scientific Corporation (MicroPort®; HKEX: 00853), is a global medical device company focusing on R&D, manufacturing, and commercialization of aortic and peripheral vascular interventional devices. Its product portfolio includes thoracic and abdominal aortic stent grafts, intraoperative stents, drug-coated PTA balloon catheters, and PTA balloon catheters. At Endovastec™, we are breaking barriers and accelerating access to provide trustworthy and universal access to state-of-the-art solutions for prolonging and reshaping life, and to build a people-centric enterprise as a global leader of evolving and emerging medical technologies through continuous innovation.
More information is available at www.endovastec.com.